

เอกสารอ้างอิง

1. Davis RC, Hobbs FD, Lip GY. *ABC of heart failure: History and epidemiology*. BMJ 2000; 320:39-42.
2. Vorasettakarnkij Y, Somabutr C, Suithichaiyakul T. *Evaluation of Treatment of Heart Failure in King Chulalongkorn Hospital*. Thai Heart J 2006;19:73-82
3. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. *EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population*. Eur Heart J 2006;27:2725-36.
4. Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson TB, Flegal K. *Heart Disease and Stroke Statistics 2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee*. Circulation 2009;119:e21-e181.
5. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. *Prevalence of heart failure and left ventricular dysfunction in the general population*. Eur Heart J 1999; 20:447-55.
6. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. *Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study*. Eur Heart J 2004;25:1614-9.
7. สำนักนโยบายและยุทธศาสตร์ กระทรวงสาธารณสุข. 10 ลำดับการตายปี 2550 [ออนไลน์]. นนทบุรี: กระทรวงสาธารณสุข; 2550 [cited 2009 August 9]. Available from: <http://bps.ops.moph.go.th/2.3.4-50.pdf>
8. สำนักโรคไม่ติดต่อ กรมควบคุมโรค กระทรวงสาธารณสุข. รายงานประจำปีงบประมาณ 2550. นนทบุรี: กระทรวงสาธารณสุข; 2551.
9. สำนักโรคไม่ติดต่อ กรมควบคุมโรค กระทรวงสาธารณสุข. จำนวนและอัตราป่วยด้วยโรคหัวใจขาดเลือด ปี พ.ศ. 2544-2550 [ออนไลน์]. นนทบุรี: กระทรวงสาธารณสุข; c2007 [cited 2009 August 9]. Available from: <http://www.thaincd.com/files/info/download1no68.xls>

10. สำนักโรคไม่ติดต่อ กรมควบคุมโรค กระทรวงสาธารณสุข. จำนวนและอัตราตายด้วยโรคหัวใจขาดเลือด ปี พ.ศ. 2544-2550 [ออนไลน์]. นนทบุรี: กระทรวงสาธารณสุข; c2007 [cited 2009 August 9]. Available from: <http://www.thaincd.com/files/info/download1no64.xls>
11. The SOLVD Investigators. *Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions*. N Engl J Med 1992;327:685-91.
12. The CONSENSUS Trial Study Group. *Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)*. N Engl J Med 1987;316:1429-35.
13. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure*. Lancet 1993;342:821-8.
14. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, et al. *A clinical trial of the angiotensin converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction*. N Engl J Med 1995;333:1670-6.
15. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. *Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators*. N Engl J Med 1992;327:669-77.
16. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. *Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group*. Eur Heart J 1995;16:1892-9.
17. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. *Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group*. Circulation 1999;100:2312-8.
18. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. *Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II*. Lancet 2000; 355:1582-7.

19. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. *Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM Overall programme*. Lancet 2003;362:759-66.
20. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. *Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study*. J Am Coll Cardiol 2002;40:970-5.
21. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. *The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group*. N Engl J Med 1996;334:1349-55.
22. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjeksus J, et al. *Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)*. MERIT-HF Study Group. JAMA 2000;283:1295-302.
23. CIBIS-II Investigators and committees. *The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial*. Lancet 1999; 353: 9-13.
24. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. *Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)*. Eur Heart J 2005; 26:215-25.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. *The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators*. N Engl J Med 1999;341:709-17.
26. Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B, et al. *Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction*. N Engl J Med 2003;348:1309-21.
27. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiat TG, et al. *2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation*. J Am Coll Cardiol 2009;53:e1-e90.

28. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. *ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).* Eur Heart J 2008;29:2388-442.
29. Heart Failure Society of America. *HFSA 2006 Comprehensive Heart Failure Practice Guideline.* J Card Fail 2006;12:e1-122.
30. National Institute for Clinical Excellence. *Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care* [Online]. London: National Institute for Clinical Excellence; 2003 [cited 2009 July 17] Available at: <http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf>
31. Scottish Intercollegiate Guidelines Network. *Management of Chronic Heart Failure: A national clinical guideline* [Online]. Edinburgh: Scottish Intercollegiate Guidelines Network; 2007 [cited 2009 July 17] Available at: <http://www.sign.ac.uk/pdf/sign95.pdf>
32. สมาคมแพทย์โรคหัวใจแห่งประเทศไทยในพระบรมราชูปถัมภ์ และชมรมหัวใจล้มเหลวแห่งประเทศไทย. *แนวทางการปฏิบัติมาตรฐานเพื่อการวินิจฉัยและการดูแลรักษาผู้ป่วยภาวะหัวใจล้มเหลว.* กรุงเทพฯ: สมาคมแพทย์โรคหัวใจแห่งประเทศไทย; 2551.
33. Havranek EP, Abrams F, Stevens E, Parker K. *Determinants of mortality in elderly patients with heart failure.* Arch Intern Med 1998;158:2024-8.
34. Gambassi G, Lapane K, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, et al. *Effects of angiotensin converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure.* Arch Intern Med 2000;160:53-60.
35. Ahmed A, Maisiak R, Allman RM, DeLong JF, Farmer R. *Heart failure mortality among older medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme use.* South Med J 2003;96:124-9.
36. Maggioni AP, Sinagra G, Opasich C, Geraci E, Gorini M, Gronda E, et al. *Treatment of chronic heart failure with beta-adrenergic blockade beyond controlled clinical trials: the BRING UP experience.* Heart 2003;89:299-305.

37. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, et al. *Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey*. Lancet 2002;360:1631-9.
38. Komajda M, Follath F, Swedberg K, Cleland JG, Aguilar JC, Cohen-Solal A, et al. *The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. The study group of diagnosis of the Working Group on Heart Failure of the European Society of Cardiology*. Eur Heart J 2003;24:464-74.
39. Lenzen MJ, Boersma E, Scholte op Reimer WJ, Balk AH, Komajda M, et al. *Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure*. Eur Heart J 2005;26:2706-13.
40. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. *Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey*. Eur Heart J 2005;26:1653-9.
41. Jotkowitz AB, Porath A, Shotan A, Mittelman M, Grossman E, Zimlichman R, et al. *Adherence to Guidelines for Patients Hospitalized with Heart Failure: A Nationwide Survey*. IMAJ 2006;8:875-9.
42. de Groote P, Isnard R, Assayag P, Clerson P, Ducardonnet A, Galinier M. *Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey*. Eur J Heart Fail 2007;9:1205-11.
43. Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. *Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy*. Clin Res Cardiol 2008;97:244-52.
44. Ohsaka T, Inomata T, Naruke T, Shinagawa H, Koitabashi T, Nishii M, et al. *Clinical Impact of Adherence to Guidelines on the Outcome of Chronic Heart Failure in Japan*. Int Heart J 2008;49:59-73.
45. Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. *Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: A prospective cohort study*. Eur J Heart Fail 2008;10:1236-45.

46. Kanoksilp A, Hengrussamee K, Wuthiwaropas P. *A Comparison of One-Year Outcome in Adult Patients with Heart Failure in Two Medical Setting: Heart Failure Clinic and Daily Physician Practice*. J Med Assoc Thai 2009;92 :466-70.
47. ศุภนิมิต ทิพนชุมเหเถียร. *Drug Therapy of Congestive Heart Failure* [Online]. เชียงใหม่: คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่; [cited 2009 July 20] Available at: http://www.med.cmu.ac.th/dept/pharmaco/data_391.392/392-05CHF.pdf
48. อภิชาติ สุคนธสรณ์ และ รังสฤษฎ์ กาญจนวณิชย์, บรรณาธิการ. *Heart Failure*. เชียงใหม่: ไอแอมอาร์เก็นเนอเรชั่นแอ็ดเวอร์ไทซ์; 2547
49. อารมณ เจษฎาญาณเมธา. *หลักการใช้น้ำยาในโรคหัวใจล้มเหลวเรื้อรัง (Principles of Pharmacotherapy in Chronic Heart Failure)* [Online]. พิษณุโลก: คณะเภสัชศาสตร์ มหาวิทยาลัยนเรศวร; 2549 [cited 2009 July 19] Available at: http://www.pha.nu.ac.th/apirukw/ambu/uploads/C2CAB_Handout_Pharmacotherapeutics_HF_49.pdf
50. Parker RB, Patterson JH, Johnson JA. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: A Pathophysiologic Approach*. 6th ed. USA: The McGraw-Hill; 2005. p. 219-30.
51. กษกรณ ก้นไชยศักดิ์ กนกวรรณ เกตุสุด และปิยฉัตร ชมสวน. *ความสามารถในการทนต่อการใช้น้ำยา กลุ่ม β -blockers ในผู้ป่วยโรคหัวใจล้มเหลวชนิด left ventricular systolic dysfunction [ปัญหาพิเศษ]*. เชียงใหม่: มหาวิทยาลัยเชียงใหม่; 2552
52. Ho KKL, Pinsky JL, Kannel WB et al. *The epidemiology of heart failure: the Framingham Study*. J Am Coll Cardiol 1993;22(Suppl. A):6A–13A.
53. U.S. Department of Health and Human Services. *The Health Consequences of Smoking : A report of the Surgeon General*. Atlanta: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
54. U.S. Department of Health and Human Services. *The Health Benefits of Smoking Cessation: A report of the Surgeon General*. Rockville: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990.
55. Remme WJ, Swedberg K, Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. *Guidelines for the diagnosis and treatment of chronic heart failure*. Eur Heart J 2001;22:1527–60.

56. Houghton AR, Cowley AJ. *Why are angiotensin converting enzyme inhibitors under-utilised in the treatment of heart failure by general practitioners?*. Int J Cardiol 1997;59:7–10.
57. Chin MH, Friedmann PD, Cassel CK, Lang RM. *Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure*. J Gen Intern Med 1997;12:523-30.
58. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. *Characteristics and outcomes of patients with heart failure in general practices and hospitals*. Circ J 2007;71:449-54.
59. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. *Combination of isosorbide dinitrate and hydralazine in blacks with heart failure*. N Engl J Med 2004;351:2049-57.
60. Lohitnavy O, Lohitnavy M, Taytiwat P, Polnok S. *Bioequivalence study of enalapril tablets in healthy Thai male volunteers*. J Med Assoc Thai 2002;85:716-21.
61. Remme WJ, McMurray JJV, Hobb FDR, Cohen-Solal A, Lopez-Sendon J, Boccanelli A, et al. *Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians*. Eur Heart J 2008;29:1739-52.
62. Phillips LS, Branch Jr. WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. *Clinical inertia*. Ann Intern Med 2001;135:825-34.
63. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PC, et al. *Why Don't Physicians Follow Clinical Practice Guidelines? A Framework for Improvement*. JAMA 1999;282:1458-65.
64. Sturm HB, Haaijer-Ruskampa FM, Veegerb NJ, Balje-Volkersb CP, Swedbergc K, van Gilsta WH. *The relevance of comorbidities for heart failure treatment in primary care: A European survey*. Eur J Heart Fail 2006;8:31-7.
65. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. *The Seattle Heart Failure Model: prediction of survival in heart failure*. Circulation 2006;113:1424-33.
66. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. *Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure*. ATLAS Study Group. Circulation 1999;100:2312–8.

67. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P, on behalf of CIBIS II investigators. *Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)*. Eur Heart J 2003;24:552–9.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved